Clinical knowledge · On demand

Expert medicine,
clearly explained.

A curated library of doctor-led videos on PSMA therapy, PRRT, TARE, neuroendocrine tumours and the science behind precision nuclear medicine.

15Expert videos

4Clinical themes

2Nuclear physicians

Featured discussion

Can Lu-PSMA Therapy Defer ADT?

A focused discussion of early Lu-PSMA therapy, androgen deprivation therapy and the evidence questions that matter in hormone-sensitive or oligometastatic prostate cancer.

Browse the complete library.

15 videos

Prostate cancer2024

When to Consider Lu-PSMA for Prostate Cancer

Dr. Dharmender Malik explains where Lu-177 PSMA therapy may fit in the treatment pathway for selected patients with prostate cancer.

Dr. Dharmender Malik

Prostate cancer2024

Can Lu-PSMA Therapy Defer ADT?

A focused discussion of early Lu-PSMA therapy, androgen deprivation therapy and the evidence questions that matter in hormone-sensitive or oligometastatic prostate cancer.

Dr. Ishita B. Sen

Radioligand science2024

Why Accurate Radioligand Labelling Matters

A clear explanation of the radioactive isotope, targeting ligand and quality controls that must come together before radioligand therapy can be delivered.

Dr. Ishita B. Sen

TARE & liver cancer2024

Order, Map & Treat: The OMT Approach to TARE

An introduction to the Order, Map & Treat pathway and how coordinated planning can streamline selected TARE procedures.

Dr. Ishita B. Sen

TARE & liver cancer2024

TARE vs TACE: How the Procedures Differ

A concise comparison of TARE and TACE, including the clinical factors specialists consider when discussing liver-directed treatment.

Dr. Ishita B. Sen

Patient pathway2023

Why Patients Choose Lutetium Therapy in India

An overview of the clinical and travel pathway for international patients considering Lutetium therapy at FMRI in Gurugram, India.

Patient pathway overview

Prostate cancer2023

What Is PSMA Therapy?

A patient-friendly introduction to PSMA expression, PSMA-targeted imaging and radioligand therapy for prostate cancer.

Dr. Ishita B. Sen

TARE & liver cancer2022

TARE: A Step-by-Step Treatment Overview

A practical overview of transarterial radioembolisation, from hepatic-artery mapping and dosimetry to microsphere delivery.

Dr. Ishita B. Sen

PRRT & NETs2021

PRRT Therapy: What Patients Should Know

An accessible introduction to peptide receptor radionuclide therapy for somatostatin-receptor-positive neuroendocrine tumours.

Dr. Ishita B. Sen

Prostate cancer2021

Actinium-225 vs Lutetium-177 PSMA Therapy

A clinical explainer on alpha- and beta-emitting PSMA therapies, their different radiation characteristics and the importance of patient selection.

Dr. Ishita B. Sen

PRRT & NETs2021

Treating Liver Metastases in Neuroendocrine Tumours

A discussion of treatment planning when neuroendocrine tumours present with a substantial burden of liver metastases.

Dr. Ishita B. Sen

PRRT & NETs2021

How Doctors Assess Whether PRRT Is Appropriate

A structured explanation of the scans, tumour biology, prior treatment and organ-function checks used when considering PRRT.

Dr. Ishita B. Sen

TARE & liver cancer2021

TARE for Neuroendocrine Tumour Liver Metastases

A focused comparison of TARE and TACE in patients with neuroendocrine tumour metastases involving the liver.

Dr. Ishita B. Sen

Archive2021

Cancer Care During COVID-19

An archived 2021 video discussing continuity of cancer care during the COVID-19 pandemic. Current decisions should follow present-day medical guidance.

Dr. Ishita B. Sen

TARE & liver cancer2021

Long-Term Considerations After Y-90 Treatment

An overview of longer-term considerations after Yttrium-90 treatment and the role of follow-up in patients receiving liver-directed radioembolisation.

Dr. Ishita B. Sen

No videos match this search. Try a broader topic.

Individual clinical review

Videos inform. Your scans and records decide.

These explainers provide general information. Treatment recommendations require current imaging, pathology, prior-treatment history, organ-function assessment and review by the treating team.

Discuss your case